WSC
MRNA icon

Wellington Shields & Co’s Moderna MRNA Stock Holding History

Wellington Shields & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,763
Closed -$452K – 304
2024
Q3 		$452K Sell
6,763
-13
-0.2% -$1.19K 0.14% 133
2024
Q2 		$805K Sell
6,776
-1,600
-19% -$202K 0.26% 91
2024
Q1 		$893K Buy
8,376
+2,570
+44% +$259K 0.3% 83
2023
Q4 		$577K Sell
5,806
-820
-12% -$69K 0.21% 103
2023
Q3 		$684K Buy
6,626
+2,655
+67% +$296K 0.17% 88
2023
Q2 		$482K Sell
3,971
-429
-10% -$57.2K 0.11% 119
2023
Q1 		$676K Buy
4,400
+24
+0.5% +$3.96K 0.15% 89
2022
Q4 		$786K Sell
4,376
-930
-18% -$152K 0.18% 77
2022
Q3 		$627K Sell
5,306
-136
-2% -$20.6K 0.27% 86
2022
Q2 		$777K Buy
5,442
+2,065
+61% +$295K 0.19% 75
2022
Q1 		$582K Buy
3,377
+1,345
+66% +$226K 0.19% 110
2021
Q4 		$516K Buy
+2,032
New +$594K 0.1% 120

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Shields & Co's MRNA Position: Q4 2024 in Review

Wellington Shields & Co sold out of Moderna (MRNA) in Q4 2024, closing a stake of 6,763 shares — an estimated $452K sold.

Wellington Shields & Co first reported a position in MRNA in Q4 2021 and held it in 12 quarters. The position peaked at $893K in Q1 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Wellington Shields & Co reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Wellington Shields & Co sold 6,763 Moderna shares in Q4 2024, an estimated $452K.
  • Wellington Shields & Co first reported a position in Moderna in Q4 2021 and held it in 12 quarters.
  • Wellington Shields & Co's Moderna position peaked at $893K in Q1 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Wellington Shields & Co's 13F filing for Q4 2024, filed 10 Feb 2025.